An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain
Trial ID or NCT#
Status
Purpose
The primary objective of this study is to characterize the pharmacokinetics and pharmacodynamics of hydromorphone oral solution in pediatric subjects aged 28 days to 16 years inclusive. The secondary objectives are to characterize the safety and efficacy of hydromorphone oral solution in pediatric subjects aged 28 days to 16 years inclusive.
Official Title
A Multi-center, Open-label, Dose Titration Study Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Hydromorphone Oral Solution in Subjects From 28 Days to 16 Years of Age, Who Require Opioid Analgesics for Postoperative Pain
Eligibility Criteria
- * Pediatric subjects aged 28 days to 16 years,* Prospective subjects anticipated to have postoperative pain requiring oral opioid analgesics for at least 24 hours (up to 48 hours) following postoperative parenteral analgesia (up to 48 hours),* Prospective subjects have received no more than a total of 7 doses of opioids in the 30 days prior to surgery.
- * Prospective subjects with clinically significant hepatic or renal dysfunction and impaired cardiac and/or respiratory reserve,* Prospective subjects who have received opioid analgesic therapy other than hydromorphone or morphine sulfate during the up to 48-hour postoperative period prior to administration of first dose of oral hydromorphone,* Prospective subjects who have received regional anesthetic blockade OR analgesic treatment with nonopioid medication within 6 hours prior to administration of first dose of oral hydromorphone.
- Other protocol-specific inclusion/exclusion criteria may apply.
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Greg Hammer
6507237835
View on ClinicalTrials.gov